Ripretinib - Deciphera Pharmaceuticals
Alternative Names: DCC-2618; QINLOCKLatest Information Update: 14 Jun 2024
At a glance
- Originator Deciphera Pharmaceuticals
- Developer Deciphera Pharmaceuticals; Specialised Therapeutics Asia; ZAI Lab
- Class Amines; Antineoplastics; Bromobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Naphthyridines; Phenylurea compounds; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-kit expression inhibitors; TIE-2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Gastrointestinal stromal tumours
- Phase I Solid tumours; Systemic mastocytosis
- No development reported Glioblastoma
Most Recent Events
- 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
- 31 Jan 2024 Deciphera Pharmaceuticals has patent protection for ripretinib in Europe, Australia, South America, and Asia
- 18 Jan 2024 Adverse events data from a phase III INTRIGUE trial in Gastrointestinal stromal tumours presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)